Lupin rises on launching Merzee capsules in United States
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Lupin is currently trading at Rs. 785.40, up by 0.80 points or 0.10% from its previous closing of Rs. 784.60 on the BSE.
The scrip opened at Rs. 790.00 and has touched a high and low of Rs. 792.90 and Rs. 778.75 respectively. So far 45665 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1267.50 on 02-Jun-2021 and a 52 week low of Rs. 678.65 on 07-Mar-2022.
Last one week high and low of the scrip stood at Rs. 798.90 and Rs. 762.70 respectively. The current market cap of the company is Rs. 35699.01 crore.
The promoters holding in the company stood at 46.81%, while Institutions and Non-Institutions held 40.39% and 12.79% respectively.
Lupin has launched Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg, in the US market, under exclusive license, marketing and distribution agreement with Slayback Pharma LLC (Slayback). Slayback had earlier launched this product in the US in February 2021.
Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg is a generic equivalent of Taytulla (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg of Allergan Pharmaceuticals International Limited. Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules, 1 mg/20 mcg (RLD: Taytulla) had estimated annual sales of $90 million in the U.S. (IQVIA MAT February 2022).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
